> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Track for TransThera Drug
- URL: https://www.fdaweb.com/fda-fast-track-for-transthera-drug/
- Published: 2021-11-03T12:00:00.000Z
- Updated: 2026-09-14T17:21:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150512

FDA has granted fast track designation to TransThera Science’s Phase 2 product TT-00420 for treating patients with cholangiocarcinoma (CCA) who have no standard treatment options. The company [says](https://www.marketwatch.com/press-release/transthera-receives-fast-track-designation-from-fda-for-its-core-product-tt-00420-to-treat-cholangiocarcinoma-2021-11-03?tesla=y&ref=fdaweb.com) TT-00420 is a spectrum selective kinase inhibitor that is found to show high potency to a variety of clinically identified FGFR2 mutations in preclinical experiments. “The unique combination of TT-00420’s target profile and mechanism of action also allows it to effectively treat patients with heterogeneous tumors, such as CCA patients without clear biomarkers,” the company says.